Liver fibrosis in non-alcoholic fatty liver disease. Fibrosis and cirrhosis of liver
Conditions
Interventions
Intervention 1: Intervention group: (Allopurinol + standard non-alcoholic fatty liver treatment): 77 patients will be included in the study based on inclusion and exclusion criteria and will receive 3
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age 18-70 years No history of alcohol consumption Absence of other liver diseases No previous allergy to allopurinol In the case of diabetic patients, HbA1c (glycosylated hemoglobin) is less than 7% and the dose of antidiabetic medication has been stable for at least the last 3 months until the time of study entry.
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Serum creatinine more than 1.5 mg/dl Simultaneous use of drugs that interact with allopurinol Simultaneous use of drugs that cause hepatic steatosis Simultaneous use of research drugs effective on non-alcoholic fatty liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum hs-CRP (C-Reactive Protein High-Sensitivity) level. Timepoint: At the beginning and end of the study. Method of measurement: ELISA Kit.;MDA (Malondialdehyde) level in serum. Timepoint: At the beginning and end of the study. Method of measurement: (MDA) Lipid Peroxidation Kit.;Total antioxidant capacity (TAC) level in serum. Timepoint: At the beginning and end of the study. Method of measurement: Total Antioxidant Capacity Kit.;FIB-4 non-invasive score. Timepoint: At the beginning and end of the study. Method of measurement: FIB-4: (Age [yr] x AST) / ((PLT [10(9)/L]) x (?ALT?^(1/2))). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfshin Gharekhani
Tabriz University of Medical Sciences
Outcome results
None listed